Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

Figure 1 Disease progression in DIO-nonalcoholic steatohepatitis mice. A-E: Individual and composite NAFLD activity scores (NAS) and fibrosis stage; F-H: Quantitative analysis of liver lipid, galectin-3 and collagen 1a1 fractional area; I-K: Heatmap on liver transcriptome changes and expression of selected genes. ^aP < 0.05, ^cP < 0.001 vs week 0. NASH: Nonalcoholic steatohepatitis.

Figure 2 Metabolic effects of liraglutide, obeticholic acid, and elafibranor treatment in DIO-nonalcoholic steatohepatitis mice. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs vehicle controls; OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.

Figure 3 Histomorphological effects of liraglutide, obeticholic acid, and elafibranor treatment in DIO-nonalcoholic steatohepatitis mice. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs vehicle controls. OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.

Figure 4 Quantitative histological assessment of liver lipids, collagen deposition and inflammation in DIO-nonalcoholic steatohepatitis mice. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs vehicle controls. OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.

Figure 5 Hepatic global gene expression analysis in DIO-nonalcoholic steatohepatitis mice. A and B: Principal component analysis; C: Venn diagram of differentially expressed genes, compared to vehicle treatment; D: Overview of KEGG pathway-enriched gene groups; E: Relative expression of prototypic NASH genes; F: Relative expression of selected genes. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs vehicle controls. OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.

Figure 6 Metabolic effects of liraglutide, obeticholic acid, and elafibranor treatment in ob/ob-nonalcoholic steatohepatitis mice. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs vehicle controls. OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.

Figure 7 Histomorphological effects of liraglutide, obeticholic acid, and elafibranor treatment in ob/ob-nonalcoholic steatohepatitis mice. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs vehicle controls. OCA: Obeticholic acid; NASH: Nonalcoholic steatohepatitis.